Cargando…

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17

Antimicrobial resistance poses a global threat to public health. Of great concern are Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacterales with resistance to carbapenems or third-generation cephalosporins. The aim of the present study was to investigate the in vitro activity of the n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wohlfarth, Esther, Kresken, Michael, Deuchert, Fabian, Gatermann, Sören G., Pfeifer, Yvonne, Pfennigwerth, Niels, Seifert, Harald, Higgins, Paul G., Werner, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215668/ https://www.ncbi.nlm.nih.gov/pubmed/37237767 http://dx.doi.org/10.3390/antibiotics12050864

Ejemplares similares

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
por: Seifert, Harald, et al.
Publicado: (2023)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20
por: Kresken, Michael, et al.
Publicado: (2022)

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria
por: Simon, Michaela, et al.
Publicado: (2022)

Molecular surveillance reveals the emergence and dissemination of NDM-5-producing Escherichia coli high-risk clones in Germany, 2013 to 2019
por: Hans, Jörg B, et al.
Publicado: (2023)

Increase in NDM-1 and NDM-1/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022
por: Sandfort, Mirco, et al.
Publicado: (2022)

Rapid spread of OXA-244-producing Escherichia coli ST38 in Germany: insights from an integrated molecular surveillance approach; 2017 to January 2020
por: Kremer, Katrin, et al.
Publicado: (2020)

Geographical differences of carbapenem non-susceptible Enterobacterales and Acinetobacter spp. in Germany from 2017 to 2019
por: von Laer, Anja, et al.
Publicado: (2022)

IS26-Mediated Transfer of bla(NDM–1) as the Main Route of Resistance Transmission During a Polyclonal, Multispecies Outbreak in a German Hospital
por: Weber, Robert E., et al.
Publicado: (2019)

Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019
por: Haller, Sebastian, et al.
Publicado: (2019)

Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae
por: Kresken, Michael, et al.
Publicado: (2021)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
por: Ghebremedhin, Beniam, et al.
Publicado: (2021)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Molecular surveillance of carbapenemase-producing Pseudomonas aeruginosa at three medical centres in Cologne, Germany
por: Schäfer, Elena, et al.
Publicado: (2019)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

Temporal trends of the in vitro activity of tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006–2014: results of the Tigecycline Evaluation and Surveillance Trial (TEST)
por: Kresken, Michael, et al.
Publicado: (2016)

In Vitro Activity of Two Novel Antimicrobial Compounds on MDR-Resistant Clinical Isolates
por: Rima, Mariam, et al.
Publicado: (2023)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
por: Yamano, Yoshinori
Publicado: (2019)

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

2811. Real-World Experience Utilizing Cefiderocol for Serious Multidrug Resistant Gram-Negative Infections
por: Teran, Nicholas S, et al.
Publicado: (2023)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007)
por: Kresken, M., et al.
Publicado: (2009)

Complete genome sequences of eight Auritidibacter ignavus strains isolated from ear infections in Germany
por: Bähr, Tobias, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_optigm30nb9fq9t4ge5o1pmf4n